Aptamers influence the hemostatic system by activating the intrinsic coagulation pathway in an in vitro chandler-loop model

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 2, 2010, Pages 161-169

  Paul, Angela ^a   Avci Adali, Meltem ^a   Neumann, Bernd ^a   Guo, Ketai ^a   Straub, Andreas ^a   Dietz, Klaus ^b   Ziemer, Gerhard ^a   Wendel, Hans P ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Aptamer; Coagulation; Complement; Factor XII; Inflammation; Kallikrein

Indexed keywords

APTAMER; BLOOD CLOTTING FACTOR 12; COMPLEMENT; KALLIKREIN; PROTHROMBIN;

ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; DNA LIBRARY; DNA SEQUENCE; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; INFLAMMATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE COUNT;

APTAMERS, NUCLEOTIDE; BIOLOGICAL MARKERS; BLOOD COAGULATION; COMPLEMENT SYSTEM PROTEINS; DNA, SINGLE-STRANDED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FACTOR XII; HEMORHEOLOGY; HEPARIN; HIRUDINS; HUMANS; INFLAMMATION; KALLIKREINS; LEUKOCYTES; PLATELET ACTIVATION; PROTHROMBIN; SELEX APTAMER TECHNIQUE;

EID: 77949902609     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608329580     Document Type: Article

References (42)

1. Patil SD, Rhodes DG, Burgess DJ DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J. 2005 ; 7: E61 - E77.
2. Ellington AD, Szostak JW In vitro selection of RNA molecules that bind specific ligands. Nature. 1990 ; 346: 818-822.
3. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990 ; 249: 505-510.
4. Chan MY, Cohen MG, Dyke CK, et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation. 2008 b; 117: 2865-2874.
5. Chapman JA, Beckey C. Pegaptanib: a novel approach to ocular neovascularization. Ann Pharmacother. 2006 ; 40: 1322-1326.
6. Chen HW, Medley CD, Sefah K., et al. Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem. 2008 ; 3: 991-1001.
7. Lee SJ, Youn BS, Park JW, Niazi JH, Kim YS, Gu MB ssDNA aptamer-based surface plasmon resonance biosensor for the detection of retinol binding protein 4 for the early diagnosis of type 2 diabetes. Anal Chem. 2008 ; 80: 2867-2873.
8. Blank M., Blind M. Aptamers as tools for target validation. Curr Opin Chem Biol. 2005 ; 9: 336-342.
9. Mayer G., Jenne A. Aptamers in research and drug development. BioDrugs. 2004 ; 18: 351-359.
10. Zhao Q., Li XF, Le XC Aptamer-modified monolithic capillary chromatography for protein separation and detection. Anal Chem. 2008 ; 80: 3915-3920.
11. Baker BR, Lai RY, Wood MS, Doctor EH, Heeger AJ, Plaxco KW An electronic, aptamer-based small-molecule sensor for the rapid, label-free detection of cocaine in adulterated samples and biological fluids. J Am Chem Soc. 2006 ; 128: 3138-3139.
12. Chen J., Jiang J., Gao X., Liu G., Shen G., Yu R. A new aptameric biosensor for cocaine based on surface-enhanced Raman scattering spectroscopy. Chemistry. 2008 ; 14: 8374-8382.
13. Pavlov V., Zorn M., Kramer R. Probing single-stranded DNA and its biomolecular interactions through direct catalytic activation of factor XII, a protease of the blood coagulation cascade. Biochem Biophys Res Commun. 2006 ; 349: 1011-1015.
14. Kannemeier C., Shibamiya A., Nakazawa F., et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A. 2007 ; 104: 6388-6393.
15. Fuhrer G., Gallimore MJ, Heller W., Hoffmeister HE FXII. Blut. 1990 ; 61: 258-266.
16. Meijers JC, Mcmullen BA, Bouma BN The contact activation proteins: a structure/function overview. Agents Actions Suppl. 1992 ; 38 (pt 2). 219-230.
17. Yarovaya GA, Blokhina TB, Neshkova EA Contact system. New concepts on activation mechanisms and bioregulatory functions. Biochemistry (Mosc). 2002 ; 67: 13-24.
18. Weber N., Wendel HP, Ziemer G. Quality assessment of heparin coatings by their binding capacities of coagulation and complement enzymes. J Biomater Appl. 2000 ; 15: 8-22.
19. Wendel HP, Hauser N., Briquet F., Ziemer G. Hemocompatibility of medical connectors with biopassive or bioactive surface coatings. J Biomater Appl. 2002 ; 17: 5-17.
20. Straub A., Azevedo R., Beierlein W., Wendel HP, Dietz K., Ziemer G. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model. Thorac Cardiovasc Surg. 2006 ; 54: 162-167.
21. Shaw JP, Kent K., Bird J., Fishback J., Froehler B. Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucleic Acids Res. 1991 ; 19: 747-750.
22. Paterson BM, Roberts BE Structural gene identification utilizing eukaryotic cell-free translational systems. Gene Amplif Anal. 1981 ; 2: 417-437.
23. Bhindi R., Fahmy RG, Lowe HC, et al. Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am J Pathol. 2007 ; 171: 1079-1088.
24. Branch AD A good antisense molecule is hard to find. Trends Biochem Sci. 1998 ; 23: 45-50.
25. Deocaris CC, Kaul SC, Taira K., Wadhwa R. Emerging technologies: trendy RNA tools for aging research. J Gerontol A Biol Sci Med Sci. 2004 ; 59: 771-783.
26. Stull RA, Szoka FC Jr. Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. Pharm Res. 1995 ; 12: 465-483.
27. Apte RS, Modi M., Masonson H., Patel M., Whitfield L., Adamis AP Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology. 2007 ; 114: 1702-1712.
28. Vavvas D., DAmico DJ Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice. Ophthalmol Clin North Am. 2006 ; 19: 353-360.
29. Gilbert JC, Feo-Fraulini T., Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007 ; 116: 2678-2686.
30. Rusconi CP, Roberts JD, Pitoc GA, et al. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol. 2004 ; 22: 1423-1428.
31. Famulok M., Hartig JS, Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. Chem Rev. 2007 ; 107: 3715-3743.
32. Jones SW, Lindsay MA Overview of target validation and the impact of oligonucleotides. Curr Opin Mol Ther. 2004 ; 6: 546-550.
33. Ravelet C., Grosset C., Peyrin E. Liquid chromatography, electrochromatography and capillary electrophoresis applications of DNA and RNA aptamers. J Chromatogr A. 2006 ; 1117: 1-10.
34. Wlotzka B., Leva S., Eschgfaller B., et al. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci U S A. 2002 ; 99: 8898-8902.
35. Cochrane CG, Griffin JH The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol. 1982 ; 33: 241-306.
36. Colman RW, Schmaier AH The contact activation system: biochemistry and interactions of these surface-mediated defense reactions. Crit Rev Oncol Hematol. 1986 ; 5: 57-85.
37. Colman RW, Schmaier AH Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 1997 ; 90: 3819-3843.
38. Colman RW, Scott CF, Schmaier AH, Wachtfogel YT, Pixley RA, Edmunds LH Jr. Initiation of blood coagulation at artificial surfaces. Ann N Y Acad Sci. 1987 ; 516: 253-267.
39. Nakazawa F., Kannemeier C., Shibamiya A., et al. Extracellular RNA is a natural cofactor for the (auto-)activation of factor VII-activating protease (FSAP). Biochem J. 2005 ; 385: 831-838.
40. Weitz JI, Hirsh J. New anticoagulant drugs. Chest. 2001 ; 119: 95S - 107S.
41. Hojima Y., Cochrane CG, Wiggins RC, Austen KF, Stevens RL In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood. 1984 ; 63: 1453-1459.
42. Moskowitz RW, Schwartz HJ, Michel B., Ratnoff OD, Astrup T. Generation of kinin-like agents by chondroitin sulfate, heparin, chitin sulfate, and human articular cartilage: possible pathophysiologic implications. J Lab Clin Med. 1970 ; 76: 790-798.